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Intermittent or recreational exposure to sunlight 
is thought to contribute to development o f human 
cutaneous melanoma. We investigated the inci­
dence o f ras oncogene mutation in human cuta­
neous melanoma in connection to sun-exposed  
body sites in the patient> using a large series o f  
DNA samples derived from  paraffin-em bedded  
material as well as from  fre sh  tumor samples 
and cell lines. We fir s t shotv that, o f  the ras fam ­
ily, predominantly N-rns is activated (15%)» 
whereas rarely //-ras or if-ras are mutated. The 
occurrence o f N~ras mutations correlates with 
continuous exposure to sunlight o f  the prim ary  
tumor site. Of all tumors initiated on chronically 
sun-exposed body sites, 26% contained mutated 
N- ras, in contrast to 0% o f sun-protected melano­
mas. Melanoma lesions obtained from  patients 
from  North or Central Europe contained few er  
N- ras mutations (12%) as com pared with p a ­
tients from  Australia (24%). Mutations were spe­
cifically associated with nodular melanoma and 
to a lesser extent with lentigo malignant mela­
noma. N-ras mutations did not correlate with me­
tastasis or survival parameters. This s tudy iden­
tifies a subset o f  cutaneous melanomas that 
contain in the primary» lesion ultraviolet-induced 
N- ras mutations} which are maintained through 
further progression. (Am J  Pathol 1996,
149:883-893)
The incidence of cutaneous melanoma and the re­
sulting mortality have increased considerably during 
the last decade, although recent studies indicate 
that the mortality rate may be leveling off in cohorts 
born after i960 .1” 4 For the nonmelanoma skin can­
cer squamous cell carcinoma, the increasing occur­
rence has been clearly linked to the escalating levels 
of ultraviolet radiation (UVR) and also to altered sun 
habits.5 Epidemiological studies have indicated that 
a linear correlation exists between squamous cell 
carcinoma incidence and UV dose 5 In agreement 
with this notion, xeroderma pigmentosum patients 
suffering from reduced or abrogated UV damage 
repair have a 1000-fold increased risk for developing 
any type of skin cancer.03
The relationship between UV and melanoma is 
much more complex. First, this relationship is not 
dose dependent, with the exception of the develop­
ment of lentigo malignant melanoma, which, as such, 
behaves similar to nonmelanoma skin cancer. Sec­
ond, the different subtypes of melanoma each show 
a distinctive causal relationship to sun exposure.7 
Intermittent or recreational (peak) exposure to sun­
light and repeated instances of sunburn are de­
scribed to be risk factors for the development of 
m e l a n o m a , I n  contrast, occupational exposure to 
UV seems to decrease the relative risk of developing 
some forms of melanoma, suggesting that mela­
noma is not simply caused by accumulating UV 
dose.9,10 Other factors thought to be involved in 
determination of this relative risk are specific for the 
host, such as skin phototype and presence of dys- 
piastic nevi or total nevus count.11,11*
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The mutational activation through UV of ras onco­
genes and the p53 tumor suppressor gene in human 
skin cancer have been studied extensively. In squa­
mous cell carcinoma, UV-induced damage to DNA 
results in mutational activation of ras and p53 genes 
in a high proportion of primary tumors.13"’15 Particu­
larly, the p53 mutations described mainly occurred 
at lesions opposite of possible pyrimidine dimers 
and are characterized by C-^T and CC~~>TT transi­
tions, pointing to UVR as the carcinogenic agent 
involved.16 In addition, UVR induces p53 mutations 
in premalignant skin lesions in man. ’7 Furthermore, 
in xeroderma pigmentosum patients, a mutation 
spectrum indicative for UV-induced cyclobutane 
damage has been clearly shown both for the p53 
gene18 and the ras genes.19 A melanoma cell line 
derived from a xeroderma pigmentosum patient was 
shown to carry mutated N-ras.20 in vitro, ras genes 
can be activated by UVR,21,22 and in a murine 
model, ras activation was detected in UV-induced 
skin tumors.23
A number of groups have reported the presence of 
activated ras genes in human melanoma lesions.24“31 
The incidence of mutated ras varied from 6 to 36%, 
whereas most mutations were detected in N-ras and 
some in H-ras. Peculiarly, two studies also reported 
prominent K-ras activations that could not be confirmed 
by others.30,31 ras mutations have been clearly linked 
to particular stages of differentiation phenotype28 and 
to malignant progression 31 In a previous study, we 
have shown that in a group of 37 melanoma patients 7 
carried mutated N-ras, and most importantly, activation 
occurred only in primary melanomas that had been 
chronically exposed to sunlight,29
To assess the general relevance of UVR for N-ras 
activation in melanoma, we have now analyzed more 
than 250 primary melanomas, métastasés, and cell 
lines from different geographical areas in Europe 
and Australia. The overall incidence of N-ras activa­
tion was 15%, with similar frequencies detected in 
the groups of primary and metastatic lesions. Aber­
rations in the N-ras gene predominantly occur in 
primary tumors arising on chronically sun-exposed 
body sites. This study provides evidence for UVR 
being involved in the activation of the N-ras onco­
gene in a substantial group of melanomas on sun- 
exposed body sites.
Materials and Methods
Tumor Material, Histology, and Patient Data
Melanoma material was collected through the Mela­
noma Cooperative Group of the European Organiza­
tion for Research and Treatment of Cancer. Paraffin- 
embedded (archival) samples as well as purified 
DNA preparations were entered in this study. Of 
each series of paraffin slides (5 to 10 ju,m), one was 
stained using hematoxylin and eosin and diagnosis 
was confirmed by the pathologist. Tumor-rich parts 
of the slide were indicated. Data on the particular 
tumor sample (eg, Breslow thickness, Clark level of 
invasion, type of melanoma, and whether primary or 
metastasis) were provided as well as data on the 
patient’s sun history and other related subjects, such 
as skin phototype, use of UVA lamps, and indication 
of xeroderma pigmentosum, Furthermore, the pre­
cise location of the primary tumor in each case was 
indicated. Finally, follow-up data (as of December
1994) were obtained on the course of the disease, 
occurrence of metastasis, and date of death.
DNA Isolation
Tumor tissue was collected from one or two slides. 
After deparaffinization with two successive washes 
with xylene, tissue was washed with 96% ethanol 
twice and dried with acetone. Protein was digested 
in 100 fi\ of PK2 buffer (10 mmol/L Tris, pH 8.3, 1 
mmol/L EDTA, 0.5% Tween-20) containing 50 /¿g/ml 
proteinase K (Boehringer, Mannheim, Germany) 
overnight at 56°C, The resulting mixture was heated 
to 95°C for 5 minutes and stored on ice for 15 min­
utes, after which the solution was cleared by centrif­
ugation. This crude DNA extract was further purified 
using silica preparations.32 Briefly, the DNA was ad­
sorbed to silica preparations (Janssen Chimica, 
Beersse, Belgium) in guanidium-thiocyanate-con- 
taining buffer, washed, and eluted in 10 mmol/L Tris, 
pH 8t 1 mmol/L EDTA at 56°C. This material was 
stored at 4°C.
Polymerase Chain Reaction (PCR)-Single- 
Stranded Conformation Polymorphism 
(SSCP) Analysis
Of the DNA extract, 0.5 to 3 ¡j l I was used for ampli­
fication of N-ras-specific exon 1 and 2 sequences 
using the following primers: for exon 1, 5'-GACT- 
G AGTAC A A ACT G GTG G (N1a) and 5'-GGGCCT- 
CACCTCTAGGTG (N1b) were used yielding a frag­
ment of 118 bp; for exon 2, a 103-bp fragment was 
generated using 51 -GGT G AAACCT GTTT GTT G G A 
(N2a) and 5'-ATACACAGAGGAAGCCTTCG (N2b)33 
Alternatively, 5' -CT G GT GT G A A AT G ACT G AGT (N1c) 
plus N1b and 5 '-GTTAT AG ATGGT G AAACCT G (N2c) 
plus N2b were used to generate an exon 1 fragment of
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130 bp and an exon 2 fragment of 112 bp. For ampli­
fication of H-ras, the following primer sequences were 
used: 5'-CAGGCCCCTGAGGAGCATG (H1a), 5'- 
GT ATT C GT CC AC A A A AT G GTTCT (H1b), 5'-TCCTG- 
CAGGATTCCTACCGG (H2a), and 5'-GGTTCACCTG- 
TACTGGTGGA (H2b), generating fragments of 113 
and 194 bp for exons 1 and 2, respectively. For K-ras 
amplification, the following primers were employed: 5'- 
GGCCTGCTGAAAATGACTGA (K1a), 5'-GTCCTG- 
CACCAGTAATATGC (K1b), 5f-TTCCTACAGGAAG- 
CAAGTAG (K2a), and 5'-CACAAAGAAAGCCCTCCC- 
CA (K2b). The K-ras primers generated 162- and 
128-bp products for exons 1 and 2, respectively. The 
20-juJ amplification mixture further consisted of 250 
jumol/L dATP, dTTP, and dGTP, 50 /xmol/L dCTP (Phar­
macia, Woerden, The Netherlands), 0.4 ^Ci of dCTP 
(Amersham, Wycombe, UK; 3000 Ci/mmol), 50 pmol/L 
of each primer, 0.04 U of T. thermophilus DNA polymer- 
ase, and 2 ¡x\ of 10X buffer (Sphaero Q, Leiden, The 
Netherlands). Cycling was performed using the follow­
ing program: 4 minutes at 95°C; 36 cycles of 30 sec­
onds at 95°C, 60 seconds at 50°C, and 30 seconds at 
72°C; and 5 minutes at 72°C. For SSCP analysis,34 4 
of the amplified mixture was mixed with gel-loading 
buffer without NaOH. One-half of this solution was de­
natured at 95°C for 4 minutes and loaded next to the 
nondenatured sample onto an 8% polyacrylamide gel 
containing either 10% glycerol/1 X TBE (89 mmol/L Tris,
89 mmol/L boric acid, 2 mmol/L EDTA) or 5% glycerol/ 
0.5X TBE. Throughout this study it was found that con­
secutive use of both gel conditions for each sample 
yielded the most accurate information. N-ras exon 1 
mutations were more readily identified on 5% glycerol/ 
0.5X TBE gels, and exon 2 aberrations were better 
visualized using 10% glycerol/1 X TBE. Gels were run 
for 4 to 6 hours at 30 W at room temperature. Vacuum- 
dried gels were exposed to Fuji RX X-ray film for 6 to 72 
hours.
Direct Sequencing
The DNA extract was reamplified for sequence anal­
ysis as described above using 250 j^mol/L of each 
dNTP. The PCR fragment was gel purified using the 
Mermaid procedure (Siratagene, La Jolla, CA), and 
10 to 50 ng of the fragments was sequenced by 
using y-32P-labe!ed primers and the T7 system 
(Pharmacia) or by using the CircumVent procedure 
(New England Biolabs, Beverly, MA).
Statistical Analysis
Statistical analysis was carried out using the SPSS 
statistical package for Windows. Possible correla­
tions between ras mutations and several parameters, 
including primary site of the tumor, origin, and sun 
exposure, were evaluated using either the ^  analy­
sis or Fisher’s exact f-test. Multiple variables were 
tested for their relevance to the presence of N-ras 
mutations by multiple (linear) regression analysis. 
Survival of patients after diagnosis of primary or met-* 
astatic melanoma and interval between primary and 
metastatic disease were analyzed in mutation (and 
other) groups using Kaplan-Meier analysis and log- 
rank statistics.
Results
Detection of N-ras Mutations in Paraffin- 
Embedded Material
DNA samples were prescreened for aberrations in 
the genomic sequence of N-ras by using PCR-SSCP 
analysis. Usually, the procedure we followed was 
composed of two PCR experiments using different 
primer pairs for either exon 1 or exon 2 sequences of 
N-ras. Next, both exon 1 and exon 2 samples were 
run through SSCP gels using two different condi­
tions, as we found in the course of this study that 
some mutations shifted visibly better in 10% glycer­
ol/1 X TBE gels than in 5% glycerol/0.5X TBE, and 
vice versa (see Materials and Methods). The SSCP 
gels were analyzed, and samples that were sus­
pected to contain mutated ras alleles were used for 
direct sequencing analysis. Four aberrations were 
identified in a representative example of a SSCP 
analysis of 21 cell lines and fresh tumor samples 
originating from patients diagnosed in Australia (Fig­
ure 1). The simultaneous analysis of PCR products of 
exons 1 and 2 is facilitated by loading control ampli­
fications for each exon individually (Figure 1, last two 
lanes).
Different A/-ras Mutations in Primary Tumors
Paraffin-embedded material from samples 238 and 
239 (the latter histologically subdivided into parts a 
and b) were analyzed for exon 1 mutations in N-ras 
(Figure 2). Samples 239a and 239b represent two 
distinct local métastasés of primary tumor 238. Sat­
ellite 239b contains a 13Gly—>Val mutation (Figure 
2B; sequence data not shown). In contrast, both the 
primary tumor 238 and satellite lesion 239a carry a 
13Gly—>Arg mutation that is obvious in the top panel 
(Figure 2A). This demonstrates that the N13Arg mu­
tation is present in a substantial amount of tumor 
cells in the primary tumor and in local metastasis
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Figure 1. A'-tum mutations in 21 Australian melanoma saw/ties. Frag­
ments J)vm exons I and 2 o f the A'-i;in gene were amplified and  
subjected to SSCP#el electmpboivsis, using 10% glycerol and IX TBJi 
Samples are loaded as follows; lane 1, 40-786; lane 2, 40-78A: lane 
3, 40-755; I ana 4, 4 0~ 725; lane 5, 40-71 A; lane 6, 40-208; lane 7, 
40-034; lane 8, 40-  024; lane 9, 40-179; lane 10, 40- 438; lane 11, 
40-016; lane 12, 40-774A; lane 13, 40-774/S; lane 14, 40-547; lane 
15, 40-815i lane 16, 40-745; lane 17, 40- 454; lane 18, 40-798; 
lane 19, 40-4A8; lane 20, 4 0 -8 1 1; lane 21, 40-303. Lanes on the 
right o f each gel panel were loaded with control exon I amplification 
product (generated from a mixture ( l: i)  o f  wild-type and 13-val- 
mutated N-ras genomic clones), followed by control exon 2 product 
(generated from the same mixture o f plasmids). Samples carrying 
mutated N-ras are indicated with an asterisk. Sample 8 did not yield 
any detectable fragments in this particular experiment.
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tT)
cd -D
c \  on
sf
1 3 - a r g
1 3 - y a l
239a, whereas the progenitor cells for metastasis 
239b containing the N13Val mutation are not detect­
able in tumor 238 (all three tumor areas were esti­
mated to contain approximately 80 to 90% tumor 
cells). In contrast, in five other patients, different 
N-ras mutations were detected in the primary tumor 
(cf Table 1), indicating that this is a rather common
phenomenon in melanoma/'
Figure 2, N-rns mutation analysis af pu rajjin-emheddcd melanoma 
sam/>ics. Samp/es 2.16, 2A8, and 239 ( t f  Table I) were used to amplify 
AM;in exon 1 fragments. Sa ni] îles J.jO/1 and 23911 represent ticosepa- 
rable local métastasés from primary tu mur sam/¡le 2A8. Un relu lcd 
sam pie 236 shotes the gel pattern for u'tld-type yV-ra.s e.xon / PCR 
producis. A: SSCP analysis usiug 5% glycerol, 0.5X 'Mil du ring elec- 
trophoresis. B: Resuit obtaiued usiug 10% glycerol, IX THF.. Samples 
bearing mutant N-rus al/eles are marked witb an asterlsk. ()n /ix'rïght 
side of both panels the position o f fragments shifting in the gel is 
indicated by an  arrow, and the resulting amino acid substitution is 
sboien.
Fifteen Percent of All Human Cutaneous 
Melanomas Carry Mutated N-ras
Using a similar technology, point mutations in the 
K-ras and H-ras gene were determined. PCR-SSCP 
analysis of 68 tumor samples revealed only one ab­
erration in H-ras (a 12Gly—>Val substitution; cf tumor 
40-254, Table 1) and none in K-ras (Figure 3). We 
concluded from this series of samples that H-ras 
(1/68, <2%) and K-ras activation (0/68) do not play a 
significant role in the etiology of the melanomas an­
alyzed,
In total, 272 independent tumor samples, consist­
ing of 175 primary tumor samples, 63 metastases, 
and 32 cell lines (for 2 samples the origin was un­
known) were analyzed for N-ras mutations. Of 272 
samples, 42 (15%) carried one or more mutations in 
N-ras, of which all but 4 were confirmed by direct 
sequencing (Table 1).
As is apparent from Table 1, 20 tumors were found 
to contain one or more mutations in exon 1 of N-ras 
(mostly in codon 13 and only four times in codon 12), 
whereas 22 tumors carried mutations in exon 2 
(codon 61), The spectrum of amino acid substitu­
tions resulting from these mutations is more or less 
restricted to 13-val, 61-lys, 61-leu, and 61-arg. The 
three position 61 mutations were all previously 
shown to be highly transforming in focus-forming 
assays and all resulted in an approximately 10-fold 
reduced GTPase activity.35 Human N-ras genes car­
rying the four mutations generated by PCR mutagen­
esis were expressed in Rat-1 fibroblasts and found 
to be highly transforming (data not shown). Further­
more, a number of these mutated samples contained 
two different mutations at the same codon. In two 
patients it was found that distinct metastases con­
tained one of the two different mutations. These data
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Table 1. Summary o f  ras Mutations Detected in 265  Melanoma Cases
jmber Affected ras Mutation (amino
cases Subclassified diagnosis* gene and codon1 acid substitution)
2 LMM, SSM N12 GGT^CGT (arg)
8 LMM (2), SSM (3), NM (3) N13 GGT—>GTT (val)
3 LMM (1), SSM (2) N13 GGT—>GAT (asp)
2 SSM, MM N13 GGT—>CGT (arg)
7 NM (4), MM (2), unknown (1) N61 CAA’—>AAA (lys)
6 SSM (2), NM, MM (2), unknown (2) N61 GAA“—>CTA (leu)
3 SSM, NM, Unci N61 CAA->CGA (arg)
4 LMM, SSM, NM, unknown N61 NR,:
1 NM N12 GGT-*GAT (asp)
N13 GGT—>GTT (val)
2 LMM, MM N13 GGT—>GTT/GAT (val/asp)0
1 NM N13 GGT—>GTT/CGT (val/arg)
1 SSM N13 GGT~>GAT/CGT (asp/arg)
1 Unknown N61 CAA-^CTA/CGA (leu/arg)
1 NM N61 CAA—>CGA (arg)
H12 GGC—>GTC (val)
‘ Diagnosis of primary lesions was done at the collaborating institute. MM, malignant melanoma; NM, nodular melanoma; SSM, 
superficial spreading melanoma; LMM, lentigo malignant melanoma; Unci, unclassifiabie melanoma; Unknown, occult primary lesion, 
indicated are the ras gene affected and the codon that carries the mutation. N12 denotes a mutation in codon 12 of the N*ras gene. 
*NR, SSCP result only; no result from direct sequencing.
§Two different mutations are identified by direct sequencing in the same codon of the N-ras gene.
can be explained by a single event of UV adduct 
formation (see Discussion).
A/-ras Mutation Is Correlated with Chronic 
Sun Exposure of the Primary Body Site
Next, N-ras mutation frequency was analyzed ac­
cording to sun exposure of body sites where the 
primary melanomas arose (Table 2). This revealed a 
highly significant correlation between solar exposure 
and incidence of mutated N-ras (P <  0.005). Chron­
ically UV-exposed primary tumors show a twofold 
enhanced mutation incidence when compared with 
tumors induced on intermittently exposed primary 
body sites. Strikingly, 38 tumors taken from sun- 
protected sites showed no N-ras mutation at all. 
When we compared the incidence of N-ras mutation 
according to primary body sites irrespective of solar 
exposure, a similar trend, although not significant, 
was observed. The highest incidence of mutant ras 
was found in tumors arising on body sites such as 
the face or head (22%) compared with the limbs 
(15%) or the trunk (11%). Furthermore, in a subset of
90 tumors for which sun history data of the patient 
were available, we found an enhanced N-ras muta­
tion incidence associated with occupational or 
chronic exposure to sunlight when compared with 
recreational (intermittent) exposure (11 mutations in 
49 chronically exposed patients (22%) and 5 muta­
tions in 41 intermittently exposed patients (12%)). 
These observations suggest that UV dose accumu­
lation, instead of UV peak exposure, results in more 
frequent N-ras activation. The origin of the analyzed
patients was categorized into North and Central Eu­
rope (The Netherlands, Belgium, Germany, and 
France), Mediterranean area (Greece, Italy, and Is­
rael), or Australia (plus one patient originating from 
Angola, Africa). N-ras mutations occurred less fre­
quently in Northern Europe (P <  0.02) and more 
frequently in Australia (P = 0.060, not significant). An 
intriguing observation made was that male patients 
seemed to carry more N-ras-mutated melanomas 
than female patients did (27 of 140 = 19.3% for 
males and 15 of 130 = 11.5% for females; P ~ 
0.087). However, this difference could be explained 
by the fact that males in our study had experienced 
more occupational sun exposure and therefore 
showed a higher N-ras mutation incidence, Finally, in 
our series, N-ras mutation was not related to skin 
phototype (not shown). Altogether, the data stress 
the fact that melanoma incidence (related to peak or
dence follow different rules.
Prognostic/Diagnostic Significance of 
Mutated N- ras in Melanoma Patients
Mutations were found predominantly in nodular mel­
anoma (28%) and lentigo malignant melanoma 
(23%) as compared with superficial spreading (14%) 
or unclassified melanoma (4%, also including 6 
cases of acral lentlginous melanoma; Table 3). The 
group of malignant melanomas represents a number 
of tumors collected in Australia without clinical sub­
classification, of which 15% contained mutated N- 
ras. Apparently, N-ras was preferentially activated in
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Figure 3. //-ras and K-ras multi lion analysis hi human melanoma 
tumor material. PCR-SSCP analysis fo r ll-ras and  A'-ras /// .vij/w m /i’ 
reactions was carried out fo r  20 melanoma sa nifties. For both //-ras 
(top panel) and  A'-ras (bottom panel), tw //m / amfifificathtns wow 
performed fo r exons I or 2 separately, using as a template genomic 
DNAfrom mein noma cell line fGR.W, which tvas fuxviously showu (a 
he wild type fo r  N-ras, if-ras, and  A'-ras,^’ Furthermore, a control 
amf>lificaliou was done fo r  K-ras exons 1 and 2, with DNA isolated 
jhm i colon card noma cell line SW4U0, that curries a K(2-val mula­
tto n. The l i  ras mutation in sample 4 is indicated hy an asterisk ( left 
side). Samf)les I to 20 are loaded in the folio tv in# order: 40-H51, 
40-X52, 40-S54, 40-254, 40-  /«VS. 4 0 -0  Hi 40-024, 40 - 0.14, 40-  
179, 40-20S, 40-291, 40-303, 40-352, 40-35H, 40-43K 40-464, 
40-496, 4 0 - 4 9 «  40-544A, 40- 544/1
the particularly aggressive nodular melanoma as 
well as In lentigo malignant melanoma, a disease 
associated with chronic UV exposure.
N-ras activation was found to occur with similar 
frequency in primary or metastasized tumors as well 
as in cell lines (Table 4). Therefore, a subclass of 
15% of melanomas seems to exist, characterized by
an early activation (ie, in the melanoma lesion in situ) 
of an N-ras allele, that is present throughout progres­
sion to disseminated disease (Table 4), indicating 
that N-ras mutation is not involved in metastasis. This 
Is further strengthened by the observation that N-ras 
aberrations in primary melanoma were not correlated 
to Breslow thickness or Clark level of invasion in our 
study (not shown). These data also show that N-ras 
activation in melanoma cell lines is not a culture 
artifact, allowing the biological significance of ras 
activation in human melanoma to be studied using 
cell lines.
Biological Significance of N- ras Mutation in 
Melanoma
When survival analysis was performed, the presence 
of N-ras mutations did not seem to influence the total 
survival after diagnosis of the first melanoma (not 
shown). However, the survival period after diagnosis 
of metastasized disease (Figure 4A) seemed to be 
extended in melanoma patients with mutated ras 
(mean period is 31.3 months; SD = 28.0 months) as 
compared with wild-type N-ras (mean is 18.7 
months; SD = 19.7 months). This effect is not statis­
tically significant (P -  0.10), but as a trend it might 
suggest that, in contrast to findings in other human 
cancers and in contrast to its oncogene function, 
mutated ras may be a favorable prognostic factor in 
human melanoma.
A significantly (P <  0.01) extended survival was 
detected for patients from Northern and Central Eu­
rope (98 ±  7.8 months) as compared with Mediter-
ranean (125 -h 34 months) or Australian patients
(69 ± 9.5 months). The latter group of patients ex­
periences a particularly shortened (P < 0,001) inter­
val period between diagnosis of primary and meta­
static disease (Figure 4B). This may be partly 
explained by assuming that the Australian melano­
mas are diagnosed at a more advanced stage of 
disease. Alternatively, 71% of the malignant melano­
mas in this series were derived from Australia, and 
this group may represent a specifically aggressive
Table 2. Correluiion bet wam  Sun Fxposurc o f the Primary Tumor Site a n d  N- nis MuictlUm in llununi Mehinoma
Pallen ts
N-ras status
Mutated N-ras 
Wild-type ras 
Total
Sun exposure of the primary tumor site
r a  i  ^  I *  H  « k J  j y  I . * .
Chronic
19 (25.7%)* 
55 
74
Intermittent
20(13.8%)
125
145
«  . - J I  i \
•  * »  « . » i  W  .  \ v *  » « 4 i . «  f * * * » « • < f J
‘ Indicated are number oí cases and column percentages (in parentheses). 
/  «  13.4 (DF -  2); P -  0.0013.
Rare
’ <*> 1  U t  É> |  . I  , M
0 (0%) 
38 
38
Total samples
39
218
257
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Table 3. N-ras Status and  Diagnosis o f  the Primary Melanoma Lesion
Diagnosis of primary tumor
N-ras status MM LMM NM SSM
Unci/
ALM Total cases
Mutated N-ras 
Wiid-type N-ras 
Total
6 (15 .4% )
33
39
6 (2 3 .1 % )
20
26
13(27.7%)
34
47
12(14.1%)
73
85
1 (3,7%)1 
26 
27
38
186
224
Numbers represent number of cases per group, with the percentage of mutated samples within the column given in parentheses. MM, 
malignant melanoma (this group consists mainly of archival patient material from Australia and The Netherlands; no subclassification is 
known); LMM, lentigo malignant melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; Unci, unclassifiablo melanoma; 
ALM, acral lentlglnous melanoma,
^Significantly more N-ras mutations in NM (,y2 — 4.83; P <  0.05),
’•‘Lower mutation frequency [x2 -  3.83; P = 0.050; Fisher exact two-iailed, P -  0.056),
group of tumors. A third possible explanation 
emerges from the comparison of the survival of 
males and females with melanoma. In our series of 
paraffin-embedded material, two-thirds of the Aus­
tralian material was collected from male patients. 
Male patients experience a shortened period to me­
tastasis (72.2 ± 7.6 months; P -  0.039) as com­
pared with females (109.3 ±  8.3 months) and con­
sequently experience a shorter survival period (see 
Discussion).
N-ras fragments. To exclude false negative SSCP re­
sults it was necessary to use two different SSCP gel 
conditions, because not all base changes produced 
visible band-shifts under all conditions. To exclude 
false positives, all samples suspected of a mutation by 
SSCP analysis were sequenced and shown to contain 
a mutation. Initially, we also sequenced approximately 
20 samples that did not show any shifts on SSCP, 
which in no case revealed an N-ras mutation, indicating 
that the gross majority of mutations was detected by 
our prescreening procedure.
Discussion
Detection of N- ras Mutations in Paraffin- 
Embedded Melanomas by PCR-SSCP 
Analysis
The combination of PCR techniques with the sensi­
tive detection of mutated PCR fragments using SSCP 
gel electrophoresis potentially allows the genetic 
characterization of archival tumor material. This rou­
tinely paraffin-embedded material can be histologi­
cally classified and subdivided, thereby generating 
the possibility of identifying molecular genetic events 
during progression of the tumor. PCR-SSCP analysis 
has been applied to the detection of different genetic 
aberrations.33,36,37 A major problem we encountered 
during this study was the lack of any detectable PCR 
product in highly pigmented samples. In most cases, 
this could be surmounted by adsorption of DNA to 
silica particles,32 although in a minority of prepara­
tions (4 of 321) it still proved impossible to amplify
N-ras, but Not H-ras or K-ras, Mutations 
Arise in 15% of Primary Cutaneous 
Melanomas
In agreement with previous reports, 15% of all tested 
primary cutaneous melanomas carried an N-ras muta­
tion. H-ras or K-ras activation were not found in signif­
icant numbers, suggesting that only mutation of the 
N-ras gene is involved in tumor development. This cor­
roborates the findings of Albino et a l^ ,2a but contrasts 
the high incidence of K-ras mutations in human mela­
noma described by others.30,31 Remarkably, the 
H12Val mutation was detected in a melanoma cell line 
that also contained an N61Arg mutation (cf Table 1), 
allowing the conclusion that the H12Val mutation by 
itself has no functional significance.
All of the N-ras mutations described In this series 
of melanomas have been identified previously in 
other malignancies,38 Most of the N-ras amino acid 
substitutions detected in this study have been shown
Table 4. N-ras Activation Not Correlated to Late Progression o f H um an Melanoma
Type of material analyzed
N-ras status Primary tumor Metastasis
Mutated N-ras 
Wild-type N-ras 
Total
27 (15.4%) 
148 
175
10(15.9%)
53
63
Indicated are number of cases and column percentages (in parentheses).
s  «  • .  *  «-a  .  s -  » ...........; w
Cell lino
5(15.6%)
27
32
Total cases
^  .  V . S  J  • f ' . . .
42
228
270
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Figure 4, Sinvieulparameters fo r  the patient gnntpsfrom three conti­
nents carrying wiUl-type or imitated N- vm ti ¡teles. A: St uvival as mea­
sured after diet gnosis o f metastasis (Cum d.\imei-U;)) teas comparai 
fo r patients cany  lug wild-type /V-nis or imitated /V-ras, Moans are 
3J.3 ± 9 .i  mouths fo r mutated patients ( 5 o f I Ci paIici Us censored) 
and IN. 7 ± 5,1 jnoutbs(J7 o ftft censored) for witd-lype patients {V "  
O.IO, tog-rank analysis). B: The interval period betieeen diagnosis o f 
primary melanoma and metastasis (Cam d,\ipritn-mel)) teas com- 
jHired fo r  gmiips o f patients from  Northern and (,'eutrai iïitmjje, the 
Mediterranean area, and Australia ( i  Central African patient). Mean 
values are 93 ± 6.2 months (North/Central lia rape), 104 ± J3 mouths 
I Mediterranean), and 49 ± 9.1 months fo r  Australian patients ( tog- 
rank vahte li.% 1’ <  ().()()!).
35,39previously by others to be highly transforming.
We confirmed the transforming capacity of the four 
major N-ras mutants (N13Val, N61Leu, N61Lys, and 
N61Arg) in focus-forming assays. Furthermore, such 
oncogenic mutations were shown to result in im­
paired GTP hydrolysis35 and insensitivity to regula­
tion of GTPase activity by the p 120-GAP and neuro- 
fibromin.'30,41 As an example, the 61 Leu mutation 
was found to be highly oncogenic as a result of 
enhanced GTP/GDP exchange combined with de­
creased GTPase activity.42
UVR Involved in the Mutagenesis of N-ras in 
Melanoma
In carcinomas of the pancreas, lung, and colon, the 
varying mutation spectra as measured in the K-ras
gene have been interpreted as an indication for the 
etiological involvement of different carcinogens.38 
Similarly, the activation spectrum found in human 
melanomas can be indicative for a carcinogenic 
agent involved. The wild-type sequence at codons 
12, 13, and 61 of the ras genes contains sites for 
potential pyrimidine dimerization, a lesion that is fre­
quently induced by UVR,16 In this study, all observed 
point mutations occur opposite these putative pyrim­
idine dimers, ie, CCA CCA for wild-type codons 12 
and 13 of N-ras (Table 1). Moreover, the presence of 
two N-ras mutations in the same melanoma lesion in 
separate cells can be explained by one event of 
UVR-induced pyrimidine dimerization. Primary mela­
noma 83070 contains both N13Val and N13Asp mu­
tations (Table 1) in roughly equal amounts of differ­
ent cells.29 The induction of one pyrimidine dimer 
lesion in codon 13 may explain the presence of two 
mutations in different cells if the UV adduct survives 
one round of replication. In that case, two repair 
events may arise from one UV-induced lesion lead­
ing to two different mutations."13 The sequential in­
duction of two independent codon 13 lesions in two 
different cells is considered less likely.
We demonstrate that N-ras mutations in melanoma 
preferentially arise on sun-exposed body sites and 
show a UV-dose-dependent activation pattern. In 
particular, N-ras mutations are detected to a signifi­
cantly lesser degree in melanomas arising in North 
or Central European patients as compared with Aus­
tralian and Mediterranean patients. Occupational ex­
posure to sunlight elevates the incidence of mutated 
N-ras, Also, primary tumors localized in the face or 
on the head carry more mutated N-ras alleles than 
tumors arising on the trunk (chronic versus intermit­
tent exposure). This contrasts with the concept of 
melanoma induction by intermittent or peak expo­
sure to UV. On the other hand, it is not unexpected, 
as isolated molecular mutagenic events are antici­
pated to follow more simple dose-response rules. 
This study provides molecular evidence for the car­
cinogenic action of UVR in human melanoma. UV 
irradiation induces these N-ras mutations and con­
sequently lies at the molecular basis of this subset of 
melanomas. Therefore, N-ras activation can be con­
sidered as a marker for the involvement of UVR in the 
etiology of these melanomas in a fashion similar to 
p53 activation in nonmelanoma skin cancer. 
Mutation of p53 has not been investigated in large 
groups of primary melanoma, although a conclusion 
from some studies is drawn that p53 is not involved 
in the generation of primary melanoma.45 We are 
currently resolving the question of whether p53 (mu-
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tated by UVR) plays a role in this series of primary 
melanomas.
The significance of UVR for human melanoma has 
been debated for many years, because no linear 
correlation could be found between UV dose re­
ceived and relative risk of developing melanoma. 
Epidemiological data suggested that high levels of 
UV exposure may even be protective in this re­
spect.9 However, a consistent deleterious effect of 
Intermittent or recreational sun exposure has been 
observed in a number of studies,1,2 This was ex­
plained as a consequence of high doses of carcino­
genic UV (peak exposure) acting on relatively unpro­
tected skin.8' 10 Furthermore, sunburn episodes46 
during or before adolescence (induction of in­
creased numbers of nevi) and migration to sunny 
areas before the age of 109 increase the risk of 
developing nonlentigo malignant melanoma. This 
leads to a hypothetical chain of events in which UV 
initiates the development of multiple nevi in child­
hood, after which subsequent peak exposure to UV 
in young adult life promotes the formation of malig­
nant melanoma at later ages. In that sense UV may 
prove to be a complete carcinogen,16 likely also 
involved in the induction of ras mutations.
Biological Significance of Mutated N- ras in 
Melanoma Patients
In our melanoma series, no obvious correlation coufd 
be found between N-ras activation and progression, 
as defined by Clark level of invasion, Breslow thick­
ness, or tendency to metastasize (Figure 4), Be­
cause the frequency of mutations in primary tumors 
was identical to that in métastasés, N-ras activation 
is probably involved in the biology of the primary 
melanoma, although it may also contribute to pro­
gression.
In colon cancer as well as in lung cancer and 
childhood leukemia a direct detrimental prognostic 
value has been assigned to the detection of a mu­
tated ras gene 47'49 In our series of melanoma pa­
tients overall survival does not seem to differ be­
tween the group carrying mutated ras and the wild- 
type group, We screened a distinct group of patients 
with metastatic melanoma and found that ras muta­
tion was associated with favorable response to im­
munotherapy, using cnnterferon plus interleukin-2 
(U. Keilholz and A. van Elsas, unpublished). This was 
interpreted as an indication that melanoma cells car­
rying mutated N-ras are more susceptible to eradi­
cation by natural killer cells50 or by cytotoxic T lym­
phocytes.51 The possible notion that mutated ras
oncogenes may be associated with improved clini­
cal course of the disease would be remarkable. 
However, the group of melanoma patients studied in 
this contribution was not specifically selected for 
immunotherapy treatment, and only a nonsignificant 
slightly improved survival after metastatic onset was 
detected in patients with N-ras mutations (Figure 
4A).
Altogether, we suggest that the activation of the 
N-ras oncogene occurs in a subset of melanomas 
that received a substantial amount of UVR. This ac­
tivation invariably is induced in the primary lesion 
and therefore plays a role in the early stages of 
melanoma development or progression. Its signifi­
cance for metastasis and survival remains unclear.
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